Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Oncotargets and Therapy|June 9, 2016
Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinomaPierre I Karakiewicz, Louise Nott, Abhishek Joshi, et al.The Oncologist|February 13, 2020
Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK TranslocationSandip Pravin Patel, Suchita Pakkala, Nathan A Pennell, et al.Journal of Cancer Survivorship : Research and Practice|April 9, 2011
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinomaPeter C Trask, Andrew G Bushmakin, Joseph C Cappelleri, et al.Clinical Genitourinary Cancer|September 1, 2015
Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell CarcinomaBrian I Rini, Bernard Escudier, Subramanian Hariharan, et al.Clinical Genitourinary Cancer|May 11, 2019
Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS TrialSergio Bracarda, Aristotelis Bamias, Jochen Casper, et al.Japanese Journal of Clinical Oncology|May 1, 2013
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trialTakeshi Ueda, Hirotsugu Uemura, Yoshihiko Tomita, et al.Oncotargets and Therapy|June 20, 2015
Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational studyShukui Qin, Feng Bi, Jie Jin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinomaBrian I Rini, George Wilding, Gary Hudes, et al.Targeted Oncology|September 25, 2015
Effect of Renal Impairment on the Pharmacokinetics and Safety of AxitinibYing Chen, Brian I Rini, Robert J Motzer, et al.Clinical Genitourinary Cancer|March 31, 2015
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell CarcinomaBernard Escudier, Brian I Rini, Robert J Motzer, et al.Pageof 3